Badrilla’s Post

Pretty chuffed to finally get this review article out there. Highlights just one of the ways that nanomedicines can be utilised to improve clinical efficacy of cancer treatments. https://lnkd.in/gUaTYPxP

IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling https://lnkd.in/g4QeSM7P

Elaborate yet concise article on the different chimeric antigen receptor therapeutic approaches especially the ongoing research into co-stimulatory domains that can make CAR-T therapy a potent yet safe alternative to chemo or other radiation based therapy in cancer treatment by cutting down (if not eliminating) the risk of CRS and ICANS. A good summarising read if you are new to the field.

In a prospective study from Fudan University Shanghai Cancer Center, involving patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone, one-third of patients showed interlesional response heterogeneity (ILRH) on PET/CT. Patients with hetero-responding disease had significantly different PFS compared to responding and non-responding groups. ILRH on both baseline and week-13 PSMA and FDG PET/CT was found to strongly associate with conventional PFS. #mCRPC #prostatecancer #abiraterone #PETCT #ILRH #PSMA #PFS #cancerresearch https://lnkd.in/ddcimiab

Summary: Recent research has explored the combination of chemotherapy and immunotherapy for improved outcomes in colorectal cancer

Adoptive T cell therapies, like CAR-T, have revolutionized blood cancer treatment. However, treating solid tumors has remained a major challenge. Scientists at the Wyss Institute have developed a metabolic labeling technology that attaches immune-boosting cytokines directly to T cells, enhancing their ability to persist in solid tumors and destroy cancer cells. #CancerResearch #Immunotherapy #Therapeutics https://lnkd.in/eUWVa6F5

I have been fascinated with CAR-T cell therapy since 2016 when the first one named Kymirah was approved. This article is a further extension of the known science (the basic nature of science is expansion) about CAR-T cell therapy. By manipulating the receptor expression and it's affinity, better CAR-T cells are being designed known as SNAP-CAR.

First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment. https://lnkd.in/ezF-KZpk

Adaptimmune receives approval for Tecelra, the first cell therapy for synovial sarcoma Adaptimmune's Tecelra (afamitresgene autoleucel) has become the first engineered cell therapy approved by the FDA for treating solid tumors. Specifically targeting synovial sarcoma, a rare and aggressive cancer, Tecelra uses a genetically modified autologous T-cell immunotherapy to treat HLA-A*02 positive patients. This is a much needed treatment option, as this type of cancer can be extremely agressive and it is most prevalent in males under 30 years of age. Congrats to Adaptimmune for this milestone! https://lnkd.in/g_zDM6mG #medicalaffairs #clinicaldevelopment #fdaapproval #genetherapy #celltherapy

Herein authors describe how #CD28 is central to the success of current #cancerimmunotherapies and examine how new questions arising from studies of CD28 as a #clinicaltarget have enhanced our understanding of its biological role and may guide the development of future #therapeuticstrategies in #oncology. https://lnkd.in/gnZs6hUx